This Week's CGT News: First Treg Therapy Approved - Report - MDSpire
Advertisement
This Week's CGT News: First Treg Therapy Approved
First Treg-based cell therapy approved, FDA advanced therapy office faces fresh turnover, and preclinical CAR T studies target rare blood cancers and glioblastoma
Clinical Report: FDA Approves First Treg-Based Cell Therapy
Overview
The FDA has approved Tregzi, the first regulatory T cell-based immunotherapy for adults with blood cancers undergoing allogeneic hematopoietic stem cell transplantation. This therapy is approved to improve chronic graft-versus-host disease-free survival.
Background
Chronic graft-versus-host disease (GVHD) is a common complication following allogeneic hematopoietic stem cell transplantation, particularly in patients with hematologic malignancies. The approval of Tregzi provides a new therapeutic option that targets immune reconstitution while minimizing the risk of GVHD.
Data Highlights
Outcome
Tregzi Group
Standard Transplant Group
1-Year cGVHD-Free Survival
78%
38.4%
Cumulative Incidence of Moderate-to-Severe cGVHD
12.6%
44%
Key Findings
Tregzi is the first regulatory T cell-based immunotherapy approved by the FDA for blood cancer patients.
The therapy is designed to improve chronic graft-versus-host disease-free survival in patients receiving allogeneic stem cell transplants.
In the PRECISION-T trial, 78% of patients treated with Tregzi were alive without moderate or severe chronic GVHD at one year.
The incidence of serious chronic GVHD within one year was significantly lower in the Tregzi group (12.6%) compared to the standard transplant group (44%).
Common adverse reactions (≥20%) included mucositis, diarrhea, rash, and infections.
Clinical Implications
The approval of Tregzi provides a new option for clinicians managing patients undergoing allogeneic stem cell transplantation.
Conclusion
The FDA's approval of Tregzi marks a milestone in the treatment of chronic GVHD.
